# Ripretinib

Ripretinib (Qinlock, Deciphera Pharmaceuticals (Netherlands) B.V.) has 1 EU-approved indication in 1 tumour type.

## Approved indications

### Gastrointestinal stromal tumour

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | Monotherapy | 3rd line+, advanced | After three or more prior kinase inhibitors, including imatinib |

## Products

### Qinlock

- Company: Deciphera Pharmaceuticals (Netherlands) B.V.
- Target: KIT and PDGFRA kinase inhibitor
- Class: Antineoplastic agents
- ATC: L01
- EU approval: 18 Nov 2021
- Label revised: 17 Sep 2026
- Status: orphan medicine
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/qinlock-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock

Mechanism (SmPC section 5.1): Tyrosine kinase inhibitor of KIT and PDGFRA, including wild-type, primary and secondary mutant forms; also inhibits PDGFRB, TIE2, VEGFR2 and BRAF in vitro.

## Label wording

- **Ripretinib** (Qinlock), Gastrointestinal stromal tumour, 3rd line+, advanced: “QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/ripretinib